Table 2.
Changes of revised histologic classification after molecular biological analysis, which was performed in 131 patients, and the additional 34 lipomas randomly retrieved from The Netherlands Cancer Institute files to complete the lipomatous tumor spectrum
| Revision classification | Molecular biological analysis | Definitive diagnosis | Change diagnosis | |
|---|---|---|---|---|
| Lipoma (34) | Amplification + | 1 | WLS | 1/34 (3%) |
| Amplification – | 33 | Lipoma | ||
| WLS (63) | Amplification + | 47 | WLS | |
| Amplification – | 13 | Lipoma | 15/63 (23%) | |
| Translocation – | 1 | WLS | ||
| Both amplification and translocation – | 2 | Lipoma | ||
| DLS (14) | Amplification + | 9 | DLS | |
| Amplification – | 4 | PLS | 4/14 (29%) | |
| Translocation – | 1 | DLS | ||
| MLS (32) | Amplification + translocation – | 11 | WLS/DLS | |
| Amplification – | 2 | MLS | ||
| Translocation + | 18 | MLS | 12/32 (38%) | |
| Translocation – | 1 | WLS/myxofibrosarcoma | ||
| RLS (9) | Translocation + | 9 | RLS | 0/9 (0%) |
| PLS (11) | Amplification + | 5 | DLS | 5/11 (45%) |
| Amplification – | 6 | PLS | ||
| Sarcoma n.o.s. (2) | Amplification + | 1 | DLS | n.a. |
| Translocation – | 1 | WLS | ||
| 165 | 165 | 37/ 163 (23%) | ||
| n.a = 2 | ||||
| N = 165 |
WLS, well-differentiated liposarcoma, DLS dedifferentiated liposarcoma, MLS myxoid liposarcoma, RLS round cell liposarcoma, PLS pleomorphic liposarcoma, N.O.S. not otherwise specified, Amplification amplification of region 12q13-15, Translocation detection of FUS–CHOP or EWS–CHOP gene fusion
+ present, – absent